Drugs / efaproxiral
efaproxiral
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00005855 | Jul 2000 → Oct 2006 | central nervous system neoplasm | New Approaches to Brain Tumor Therapy Consortium | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00004202 | Oct 1998 → Jan 2003 | lung cancer | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT00083304 | Feb 2004 → Jun 2007 | breast cancer, metastatic neoplasm | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00055887 | Nov 2002 → ? | lung cancer | Spectrum Pharmaceuticals, Inc | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00005887 | Feb 2000 → Jan 2003 | metastatic malignant neoplasm in the brain | Spectrum Pharmaceuticals, Inc | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | efaproxiral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055887 ↗ |
| Known as | EFAPROXIRAL SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL18901 ↗ |
| Known as | RSR-13 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL18901 ↗ |
| Known as | RSR13 | “Evaluate the safety and tolerability of escalating doses of efaproxiral (RSR13) when administered concurrently with carmustine in patients with progressive or recurrent...” NCT00005855 ↗1“Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.” PMID 16135463 ↗ Sep 2005 |
| Modality | Small molecule | — CHEMBL18901 ↗ |
| Route | Intravenous | “patients receive RSR13 IV over 30 minutes, followed by fractionated radiotherapy 5 times weekly for 6-7 weeks.” NCT00004202 ↗ |